Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker CGON
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Roderick Wong | 8.51M | 9.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | RTW Investments, LP | 8.51M | 9.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | James B. Tananbaum | 4.31M | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Foresite Capital Management VI LLC | 2.37M | 2.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Foresite Capital Fund VI LP | 2.37M | 2.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Foresite Capital Opportunity Management V, LLC | 857,550 | 1.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Foresite Capital Opportunity Fund V, L.P. | 857,550 | 1.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Foresite Capital Management V, LLC | 1.08M | 1.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Foresite Capital Fund V, L.P. | 1.08M | 1.2% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Wellington Management Company LLP | 5.32M | 5.7% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Wellington Investment Advisors Holdings LLP | 5.32M | 6.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Wellington Group Holdings LLP | 5.32M | 6.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Wellington Management Group LLP | 5.32M | 6.0% | SCHEDULE 13G/A ↗ |
| Jul 27, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | BlackRock, Inc. | 6.02M | 6.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G | CGON CG Oncology, Inc. | T. Rowe Price Investment Management, Inc. | 6.72M | 8.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | CGON CG Oncology, Inc. | Roderick Wong | 6.98M | 8.3% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | CGON CG Oncology, Inc. | RTW Investments, LP | 6.98M | 8.3% | SCHEDULE 13G ↗ |
| Mar 26, 2026 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 12, 2025 | SCHEDULE 13G | CGON CG Oncology, Inc. | Wellington Management Company LLP | 5.51M | 6.9% | SCHEDULE 13G ↗ |
| Nov 12, 2025 | SCHEDULE 13G | CGON CG Oncology, Inc. | Wellington Investment Advisors Holdings LLP | 5.51M | 7.2% | SCHEDULE 13G ↗ |
| Nov 12, 2025 | SCHEDULE 13G | CGON CG Oncology, Inc. | Wellington Group Holdings LLP | 5.51M | 7.2% | SCHEDULE 13G ↗ |
| Nov 12, 2025 | SCHEDULE 13G | CGON CG Oncology, Inc. | Wellington Management Group LLP | 5.51M | 7.2% | SCHEDULE 13G ↗ |
| Oct 30, 2025 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | The Vanguard Group | 6.58M | 8.6% | SCHEDULE 13G/A ↗ |
| Oct 28, 2025 | SCHEDULE 13D/A (amended) | CGON CG Oncology, Inc. | Brian Liu | 1.54M | 2.0% | SCHEDULE 13D/A ↗ |
| Oct 28, 2025 | SCHEDULE 13D/A (amended) | CGON CG Oncology, Inc. | Seven Fleet Capital Management GP LLC | 1.52M | 1.9% | SCHEDULE 13D/A ↗ |
| Oct 28, 2025 | SCHEDULE 13D/A (amended) | CGON CG Oncology, Inc. | Seven Fleet Capital Management LP | 1.52M | 1.9% | SCHEDULE 13D/A ↗ |
| Oct 28, 2025 | SCHEDULE 13D/A (amended) | CGON CG Oncology, Inc. | Seven Fleet Master Fund LP | 1.52M | 1.9% | SCHEDULE 13D/A ↗ |
| Sep 18, 2025 | SCHEDULE 13D | CGON CG Oncology, Inc. | Juliet Tammenoms Bakker | 4.66M | 6.0% | SCHEDULE 13D ↗ |
| Sep 18, 2025 | SCHEDULE 13D | CGON CG Oncology, Inc. | Patrick G. Enright | 4.66M | 6.0% | SCHEDULE 13D ↗ |
| Sep 18, 2025 | SCHEDULE 13D | CGON CG Oncology, Inc. | Longitude Prime Fund, L.P. | 1.47M | 1.9% | SCHEDULE 13D ↗ |
| Sep 18, 2025 | SCHEDULE 13D | CGON CG Oncology, Inc. | Longitude Prime Partners, LLC | 1.47M | 1.9% | SCHEDULE 13D ↗ |
| Sep 18, 2025 | SCHEDULE 13D | CGON CG Oncology, Inc. | Longitude Venture Partners IV, L.P. | 3.19M | 4.1% | SCHEDULE 13D ↗ |
| Sep 18, 2025 | SCHEDULE 13D | CGON CG Oncology, Inc. | Longitude Capital Partners IV, LLC | 3.19M | 4.1% | SCHEDULE 13D ↗ |
| Sep 18, 2025 | SCHEDULE 13D | CGON CG Oncology, Inc. | Brian Liu | 1.52M | 2.0% | SCHEDULE 13D ↗ |
| Sep 18, 2025 | SCHEDULE 13D | CGON CG Oncology, Inc. | Seven Fleet Advisors LLC | 1.52M | 1.9% | SCHEDULE 13D ↗ |
| Sep 18, 2025 | SCHEDULE 13D | CGON CG Oncology, Inc. | Seven Fleet Partners LP | 1.52M | 1.9% | SCHEDULE 13D ↗ |
| Aug 6, 2025 | SCHEDULE 13G | CGON CG Oncology, Inc. | Abigail P. Johnson | 3.86M | 5.1% | SCHEDULE 13G ↗ |
| Aug 6, 2025 | SCHEDULE 13G | CGON CG Oncology, Inc. | FMR LLC | 3.86M | 5.1% | SCHEDULE 13G ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Chen Yu | 3.67M | 4.8% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | TCG Crossover Fund I, L.P. | 3.67M | 4.8% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | TCG Crossover GP I, LLC | 3.67M | 4.8% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Xiangmin Cui | 6.37M | 8.4% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Decheng Capital Global Healthcare GP, LLC | 1.06M | 1.4% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Decheng Capital Global Healthcare Fund (Master), LP | 1.06M | 1.4% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Decheng Capital Management IV (Cayman), LLC | 5.32M | 7.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Decheng Capital Global Life Sciences Fund IV, L.P. | 5.32M | 7.0% | SCHEDULE 13G/A ↗ |
| Jan 28, 2025 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Hong Fang Song | 4.21M | 5.5% | SCHEDULE 13G/A ↗ |
| Jan 28, 2025 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | Healthcare Seed Limited | 3.59M | 4.7% | SCHEDULE 13G/A ↗ |
| Jan 28, 2025 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | ORI Holding II Inc. | 3.00M | 4.0% | SCHEDULE 13G/A ↗ |
| Jan 28, 2025 | SCHEDULE 13G/A (amended) | CGON CG Oncology, Inc. | ORI Capital II Inc. | 3.00M | 4.0% | SCHEDULE 13G/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 7:22 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances